Capital is rotating out of stretched mid-tier pharmaceutical runners.
Investors hunting for durable returns should look past recent momentum winners and reallocate toward large complex generic manufacturers, according to Deven Choksey, Managing Director at DRChoksey Finserv. The brokerage head identified Sun Pharma, Cipla, and Dr Reddy's Laboratories as superior risk-reward bets for fresh capital deployments, anticipating a 15% to 20% medium-term upside as overseas patent cliffs unlock sustained revenue streams.
Recent pharmaceutical outperformers, by contrast, leave little margin of safety.
Choksey noted that while active pharmaceutical ingredient (API) and contract research leaders remain anchored in his personal portfolio, their sharp run-ups have priced out fresh institutional capital.
"We continue to hold them," Choksey said regarding Divi's Laboratories and Laurus Labs. "We find them a bit expensive at least at this point of time. Maybe a deep correction would be a meaningful choice to buy into."
Instead, balance sheets tilted toward complex generics and US-bound specialty pipelines offer tangible earnings visibility over the next three to five years.
Among the fresh buys... Sun Pharma, Cipla and Dr Reddy's are relatively better positioned at this point of time.
These drugmakers have spent years engineering portfolios targeting off-patent branded therapies across Western export markets. As regulatory approvals clear and patent cliffs materialize through 2029, their monetization phase begins.
| Sector / Asset | Preferred Tickers | Actionable Stance | Core Investment Thesis |
|---|---|---|---|
| Pharma (Largecap Generics) | Sun Pharma, Cipla, Dr Reddy's | Fresh Buy | Complex export pipelines; off-patent drug wave over 3–5 years; 15–20% upside |
| Pharma (API / CDMO) | Divi's Laboratories, Laurus Labs | Hold Only | High valuations after sharp rally; accumulate strictly on deep corrections |
| Jewellery (Retail) | Titan, Kalyan Jewellers | Wait / Hold | High-quality balance sheets but multiples leave no safety margin for fresh entry |
Choksey struck a similar note of valuation discipline in discretionary retail. Titan Company and Kalyan Jewellers represent exceptional operations, yet their current trading multiples offer zero downside cushion for new allocations.
Investors must pivot down the supply chain to find mispriced entry points. Choksey highlighted Shanti Gold—a recently listed vendor manufacturing for major organized jewellery chains—as a counter worth tracking for secondary margin capture. He clarified that DRChoksey Finserv does not hold an investment position in the stock.
Yet tech services present the opposite dynamic.
Despite panic that artificial intelligence will cannibalize traditional software outsourcing, Choksey remains outright constructive on Indian information technology. Global corporations are not writing their own migration architectures from scratch—they hire Indian integrators to deploy them.
"Indian IT companies are relatively better placed because we are adapters," Choksey said, pointing to accelerating order inflows across largecap IT balance sheets tied directly to AI transformation contracts.
Market Context: The domestic market rotation from pure momentum into high-visibility earnings coincides with elevated equity multiples across midcaps. By pivoting into defensive largecap drugmakers and cash-rich IT servicers, institutional portfolios are securing cash-flow backing against broader market turbulence.
For investors eyeing mid-tier engineering research and development (ER&D) providers, Choksey recommended patience. High growth rates make them compelling long-term compounders, but entries should occur exclusively on price dips rather than chasing highs.
| Jewellery (Supply Chain) | Shanti Gold | Watchlist | Supply exposure to organized retail; no institutional firm position taken |
| Information Technology | Largecap IT, Mid-tier ER&D | Accumulate | AI execution engines for global enterprises; steady project order inflows |